Advanced search
Publication Cover
Postgraduate Medicine Volume 126, 2014 - Issue 2
Submit an article Journal homepage
193
Views
19
CrossRef citations to date
0
Altmetric
Clinical Features

Achieving Serum Urate Goal: A Comparative Effectiveness Study between Allopurinol and Febuxostat

Hind Hatoum President, Hind T. Hatoum and Company, Chicago, IL; Adjunct Faculty, University of Illinois at Chicago, Chicago, IL
, PhD,
Dinesh Khanna Associate Professor of Medicine, University of Michigan, Ann Arbor, MI
, MD, MSc,
Swu–Jane Lin Adjunct Faculty, University of Illinois at Chicago, Chicago, IL
, PhD,
Kasem S. Akhras Head, Market Access Middle East Cluster, Novartis Pharmaceuticals Services AG; at time of the study, Dr Akhras was employed by Takeda Pharmaceuticals International, Inc., Deerfield, IL
, PharmD,
Aki Shiozawa Manager, Global Outcome and Epidemiology Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL
, MPH, MBA &
Puja Khanna Associate Professor of Medicine, University of Michigan, Ann Arbor, MICorrespondence[email protected]
, MD, MPH
Pages 65-75 | Published online: 13 Mar 2015

References

  • . Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–3141
  • . Khanna D, Fitzgerald JD, Khanna PP, . 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–1446
  • . Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010;22(2):165–172
  • . Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623–644
  • . Zhang W, Doherty M, Bardin T, . EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–1324
  • . Pandya BJ, Riedel AA, Swindle JP, . Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings. Curr Med Res Opin. 2011;27(4):737–744
  • . Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57(5):822–829
  • . Uloric [package insert]. Deerfield, IL: Takeda Pharmaceuticals North America Inc; 2011
  • . Becker MA, Schumacher HR, Espinoza LR, . The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63
  • . Becker MA, Schumacher HR Jr, Wortmann RL, . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461
  • . Schumacher HR Jr, Becker MA, Wortmann RL, . Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548
  • . Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–1282
  • . Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford). 2009;48( Suppl 2):ii15–ii19
  • . GE Healthcare. Clinical Data Services: New Product and Service Briefing. 2013; http://www.gehealthcare.com/usen/hit/cds/docs/CDS%20Brochure_v5pg.pdf. Accessed August 1, 2013
  • . Levey AS, Coresh J, Greene T, ; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254
  • . Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383
  • . Quan H, Sundararajan V, Halfon P, . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139
  • . Ye P, Yang S, Zhang W, . Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013;35(2):180–189
  • . Wu EQ, Patel PA, Mody RR, . Frequency, risk, and cost of goutrelated episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009;36(5):1032–1040
  • . Kleinman NL, Brook RA, Patel PA, . The impact of gout on work absence and productivity. Value Health. 2007;10(4):231–237

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.